Detalles de la búsqueda
1.
Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product.
J Transl Med;
20(1): 14, 2022 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34986854
2.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Br J Haematol;
193(2): 356-368, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33222197
3.
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.
Hematol Oncol;
39(3): 409-418, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33590502
4.
Is there a gender effect in polycythemia vera?
Ann Hematol;
100(1): 11-25, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33006021
5.
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Cancer;
126(6): 1243-1252, 2020 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31860137
6.
Disease-Specific Derangement of Circulating Endocannabinoids and N-Acylethanolamines in Myeloproliferative Neoplasms.
Int J Mol Sci;
21(9)2020 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32403407
7.
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients.
Br J Haematol;
184(3): 424-430, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30408157
8.
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function.
J Transl Med;
17(1): 250, 2019 08 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31383037
9.
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.
Ann Hematol;
98(4): 889-896, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30515542
10.
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.
Br J Haematol;
183(1): 35-46, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30010187
11.
Comparison of JAK2V617F -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology.
Hematol Oncol;
36(1): 269-275, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28509339
12.
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.
Hematol Oncol;
2018 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29624703
13.
Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34+ Cells.
Mediators Inflamm;
2018: 5974613, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30116149
14.
Molecular and functional characterization of CD133+ stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells.
Cytotherapy;
19(12): 1447-1461, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28917627
15.
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.
Am J Hematol;
92(1): 37-41, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27701770
16.
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients' satisfaction.
Br J Haematol;
192(2): e48-e51, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33222149
17.
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years.
Am J Hematol;
91(4): E267-72, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26799593
18.
Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly.
Mediators Inflamm;
2016: 5860657, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27672242
19.
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis.
Br J Haematol;
185(5): 987-991, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30450539
20.
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long-term study.
Am J Hematol;
89(11): 1047-50, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25103500